PDE2A抗体;PDE2A Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of PDE2A expression in Human fetal brain lysate.    

  
  

The PDE2A antibody is a crucial tool in biomedical research for studying the function and expression of phosphodiesterase 2A (PDE2A), an enzyme involved in cyclic nucleotide signaling. PDE2A belongs to the phosphodiesterase superfamily, which hydrolyzes cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), secondary messengers regulating diverse physiological processes. PDE2A uniquely hydrolyzes both cAMP and cGMP in a cGMP-dependent manner, playing roles in cardiac function, neuronal signaling, adrenal steroidogenesis, and cellular proliferation. It is expressed in tissues such as the brain, heart, adrenal glands, and platelets.

Antibodies targeting PDE2A enable researchers to detect and quantify its expression levels, localization, and activity in cells and tissues. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and enzyme-linked immunosorbent assays (ELISA). Specific PDE2A antibodies help investigate its regulatory mechanisms in diseases, including neurological disorders (e.g., Alzheimer’s disease), cardiovascular pathologies, and cancer. For example, PDE2A dysfunction has been linked to impaired memory and cardiac hypertrophy, making it a potential therapeutic target.

The development and validation of PDE2A antibodies require careful characterization to ensure specificity, as PDE isoforms share structural similarities. Researchers often use knockout controls or peptide blocking assays to confirm antibody reliability. Commercially available PDE2A antibodies vary in host species, clonality, and conjugation, offering flexibility for experimental designs. Their applications extend to drug discovery, particularly in screening PDE2A inhibitors aimed at modulating cyclic nucleotide pathways for therapeutic benefit.